What question did this study set out to answer?

To analyze fasciitis caused by nivolumab and pembrolizumab in cancer patients for improved clinical handling.

November 10, 2025International Journal of Cancer

Clinicopathological characteristics and management of nivolumab/pembrolizumab‐induced fasciitis in cancer patients

View Full Paper

Ask AI

Bookmark

Authors

JXJian Xiao ZWZiyu Wang ZXZhi Xia

Discussion

Member takes

Implication

Systematic analysis reveals diagnosis and management strategies for fasciitis in cancer patients treated with immunotherapy, highlighting effective interventions.

Key Points

To analyze fasciitis caused by nivolumab and pembrolizumab in cancer patients for improved clinical handling.
Retrospective analysis of 47 patient cases with fasciitis related to nivolumab and pembrolizumab.
Data gathered from multiple databases, encompassing relevant case reports.
Clinical characteristics, demographic data, and treatment outcomes were assessed.
83% of cases diagnosed with fasciitis; 17% with myofasciitis.
Median time from drug initiation to fasciitis onset was 11 months.
Most patients improved after drug discontinuation and steroid therapy.

Cite This Study

Xiao et al. (2025) studied this question.

synapsesocial.com/papers/69253a29c0ce034ddc357609 https://doi.org/10.1002/ijc.70237

View Full Paper

Ask AI

Bookmark

Implication

Systematic analysis reveals diagnosis and management strategies for fasciitis in cancer patients treated with immunotherapy, highlighting effective interventions.

Clinicopathological characteristics and management of nivolumab/pembrolizumab‐induced fasciitis in cancer patients

Discussion

Member takes

Implication

Key Points

Cite This Study

Clinicopathological characteristics and management of nivolumab/pembrolizumab‐induced fasciitis in cancer patients

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider